المؤلفون: MA Dimopoulos, A Oriol, H Nahi, J San-Miguel, NJ Bahlis, SZ Usmani, N Rabin, RZ Orlowski, K Suzuki, T Plesner, SS Yoon, D Ben Yehuda, PG Richardson, H Goldschmidt, D Reece, T Ahmadi, X Qin, W Garvin Mayo, X Gai, J Carey, R Carson, P Moreau

المصدر: HemaSphere, Vol 6, Pp 13-13 (2022)

مصطلحات موضوعية: Diseases of the blood and blood-forming organs, RC633-647.5

وصف الملف: electronic resource

Relation: http://journals.lww.com/10.1097/01.HS9.0000829592.26407.09; https://doaj.org/toc/2572-9241

URL الوصول: https://doaj.org/article/818f4ede131c44239f6341ffef8f73d8

المؤلفون: AK Nooka, LJ Costa, CJ Gasparetto, PG Richardson, DS Siegel, A Chari, S Lentzsch, S Jagannath, J. Mikhael

المصدر: Clinical Lymphoma Myeloma and Leukemia. 22:e526-e531

مصطلحات موضوعية: Adult, Cancer Research, Consensus, Hydrazines, Oncology, Antineoplastic Combined Chemotherapy Protocols, Humans, Hematology, Triazoles, Multiple Myeloma, Dexamethasone

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0e4f154fc17c0bdb11485b4653167d7
https://doi.org/10.1016/j.clml.2022.01.014

المؤلفون: Sk Kumar, Lee, J., Jj Lahuerta, Morgan, G., Pg Richardson, Crowley, J., Haessler, J., Feather, J., Hoering, A., Philippe Moreau, Xavier Leleu, Benjamin Van Camp, Ivan Van Riet, Isabelle Vande Broek, Karin Vanderkerken

المساهمون: Hematology

المصدر: Vrije Universiteit Brussel

مصطلحات موضوعية: multiple myeloma

URL الوصول: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::59eb2238d303803614455d685a8cc572
https://biblio.vub.ac.be/vubir/risk-of-progression-and-survival-in-multiple-myeloma-relapsing-after-therapy-with-imids-and-bortezomib-a-multicenter-international-myeloma-working-group-study(aa2cf1ce-b4e1-4e34-910c-b5c321e35026).html

المؤلفون: PG Richardson, R Rosovsky, F Hong, D Tocco, B Connell, C Mitsiades, R Schlossman, IM Ghobrial, NC Munshi, L Lockridge, D Warren, G Bradwin, M Doyle, R Soiffer, KC Anderson, E Weller

المصدر: Clinical Lymphoma and Myeloma. 9:S55

مصطلحات موضوعية: Oncology, Stress (mechanics), Cancer Research, medicine.medical_specialty, business.industry, Internal medicine, medicine, Hematology, General Medicine, medicine.disease, business, Multiple myeloma

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::2ec7cafbd946a44b2adc9c2d31b5df47
https://doi.org/10.1016/s1557-9190(11)70549-2

المؤلفون: Kapoor P; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA., Nathwani N; Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, California, USA., Jelinek T; Department of Hematooncology, University Hospital Ostrava and University of Ostrava, Ostrava, Czech Republic., Pour L; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic., Perrot A; Department of Hematology, Institut Universitaire du Cancer de Toulouse, Toulouse, France., Dimopoulos MA; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece., Huang SY; Department of Hematology, National Taiwan University Hospital, Taipei, Taiwan., Spicka I; First Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic., Chhabra S; Division of Hematology and Oncology, Department of Medicine, Mayo Clinic Arizona, Phoenix, Arizona, USA., Lichtman E; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.; Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Mateos MV; Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), University of Salamanca, Salamanca, Spain., Kanagavel D; Research and Development, Sanofi, Research and Development, Vitry-sur-Seine, France., Zhao L; Research and Development, Sanofi, Research and Development, Shanghai, China., Guillemin-Paveau H; Research and Development, Sanofi, Research and Development, Vitry-sur-Seine, France., Macé S; Research and Development, Sanofi, Research and Development, Vitry-sur-Seine, France., van de Velde H; Research and Development, Sanofi, Research and Development, Cambridge, Massachusetts, USA., Richardson PG; Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center, Boston, Massachusetts, USA.

المصدر: European journal of haematology [Eur J Haematol] 2024 Jul 12. Date of Electronic Publication: 2024 Jul 12.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Blackwell Country of Publication: England NLM ID: 8703985 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0609 (Electronic) Linking ISSN: 09024441 NLM ISO Abbreviation: Eur J Haematol Subsets: MEDLINE

المؤلفون: Chari A; Icahn School of Medicine at Mount Sinai, New York, NY, USA. ajai.chari@ucsf.edu., Kaufman JL; Winship Cancer Institute, Emory University, Atlanta, GA, USA., Laubach J; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Sborov DW; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA., Reeves B; University of North Carolina-Department of Medicine-Chapel Hill, Chapel Hill, NC, USA., Rodriguez C; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Silbermann R; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Costa LJ; University of Alabama at Birmingham, Birmingham, AL, USA., Anderson LD Jr; Myeloma, Waldenstrӧm's and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA., Nathwani N; Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Shah N; University of California San Francisco, San Francisco, CA, USA., Bumma N; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Holstein SA; Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA., Costello C; Moores Cancer Center, University of California San Diego, La Jolla, CA, USA., Jakubowiak A; University of Chicago Medical Center, Chicago, IL, USA., Wildes TM; Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA., Orlowski RZ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Shain KH; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Cowan AJ; Clinical Research Division, Fred Hutch Cancer Center, Seattle, WA, USA., Pei H; Janssen Research & Development, LLC, Titusville, NJ, USA., Cortoos A; Janssen Scientific Affairs, LLC, Horsham, PA, USA., Patel S; Janssen Scientific Affairs, LLC, Horsham, PA, USA., Lin TS; Janssen Scientific Affairs, LLC, Horsham, PA, USA., Voorhees PM; Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC, USA. Peter.Voorhees@atriumhealth.org., Usmani SZ; Memorial Sloan Kettering Cancer Center, New York, NY, USA. usmanis@mskcc.org., Richardson PG; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

المصدر: Blood cancer journal [Blood Cancer J] 2024 Jul 08; Vol. 14 (1), pp. 107. Date of Electronic Publication: 2024 Jul 08.

نوع المنشور: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/drug therapy , Multiple Myeloma*/mortality , Multiple Myeloma*/therapy , Multiple Myeloma*/diagnosis , Antibodies, Monoclonal*/therapeutic use , Antibodies, Monoclonal*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Aged ; Female ; Male ; Middle Aged ; Adult ; Dexamethasone/administration & dosage ; Dexamethasone/therapeutic use ; Bortezomib/therapeutic use ; Bortezomib/administration & dosage ; Lenalidomide/therapeutic use ; Lenalidomide/administration & dosage

المؤلفون: Schjesvold FH; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway. fredrikschjesvold@gmail.com., Ludwig H; Department of Medicine I, Center for Medical Oncology and Hematology with Outpatient Department and Palliative Care, Wilhelminen Cancer Research Institute, Vienna., Delimpasi S; Bone Marrow Transplantation Unit and Department of Hematology, Evangelismos Hospital, Athens, Greece., Robak P; Department of Hemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic., Coriu D; University of Medicine and Pharmacy 'Carol Davila', Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest, Romania., Tomczak W; Department of Hemato-Oncology and Bone Marrow Transplantation, Medical University of Lublin., Pour L; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Babak Myeloma Group, Faculty of Medicine, Masaryk University, Brno, Czech Republic., Spicka I; 1st Department of Medicine - Department of Hematology, First Faculty of Medicine, Charles University and General Hospital in Prague, Prague, Czech Republic., Dimopoulos MA; Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece., Masszi T; Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary., Chernova NG; National Research Center for Haematology, Moscow, Russia., Sandberg A; Oncopeptides AB, Stockholm, Sweden., Thuresson M; Oncopeptides AB, Stockholm, Sweden., Norin S; Oncopeptides AB, Stockholm, Sweden., Bakker NA; Oncopeptides AB, Stockholm, Sweden., Mateos MV; Hospital Clínico Universitario de Salamanca/IBSAL/CIC, Salamanca, Spain., Richardson PG; Dana-Farber Cancer Institute, Boston, MA., Sonneveld P; Erasmus MC Cancer Institute, Rotterdam.

المصدر: Haematologica [Haematologica] 2024 Jul 01; Vol. 109 (7), pp. 2331-2336. Date of Electronic Publication: 2024 Jul 01.

نوع المنشور: Letter; Clinical Trial, Phase III; Multicenter Study; Journal Article

بيانات الدورية: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/drug therapy , Dexamethasone*/therapeutic use , Dexamethasone*/administration & dosage , Quality of Life* , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Phenylalanine/therapeutic use ; Phenylalanine/analogs & derivatives ; Female ; Male ; Drug Resistance, Neoplasm ; Treatment Outcome ; Neoplasm Recurrence, Local/drug therapy ; Recurrence ; Middle Aged ; Aged

المؤلفون: Mo CC; Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Boston, MA, USA., Richardson E; Department of Medicine, Warren Alpert Medical School at Brown University, Providence, RI, USA., Calabretta E; Department of Biomedical Sciences, Humanitas University, and IRCCS Humanitas Research Hospital, Milan, Italy; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Corrado F; Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Boston, MA, USA; Department of Biomedical Sciences, Humanitas University, and IRCCS Humanitas Research Hospital, Milan, Italy; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Kocoglu MH; Department of Medicine, University of Maryland School of Medicine, and Transplant and Cellular Therapy Program, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA., Baron RM; Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Connors JM; Division of Hematology, Brigham and Women's Hospital, Boston, MA, USA., Iacobelli M; Techitra S.r.l., Milan, Italy., Wei LJ; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA., Rapoport AP; Department of Medicine, University of Maryland School of Medicine, and Transplant and Cellular Therapy Program, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA., Díaz-Ricart M; Hematopathology, Pathology Department, CDB, Hospital Clinic, and IDIBAPS, Barcelona, Spain, and Barcelona Endothelium Team, Barcelona, Spain., Moraleda JM; Department of Medicine, Faculty of Medicine, Institute of Biomedical Research (IMIB-Pascual Parrilla), University of Murcia, Murcia, Spain., Carlo-Stella C; Department of Biomedical Sciences, Humanitas University, and IRCCS Humanitas Research Hospital, Milan, Italy., Richardson PG; Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Boston, MA, USA. Electronic address: Paul_Richardson@dfci.harvard.edu.

المصدر: Blood reviews [Blood Rev] 2024 Jul; Vol. 66, pp. 101218. Date of Electronic Publication: 2024 Jun 03.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 8708558 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1681 (Electronic) Linking ISSN: 0268960X NLM ISO Abbreviation: Blood Rev Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/therapy , Multiple Myeloma*/complications , Multiple Myeloma*/immunology , COVID-19*/complications , COVID-19*/immunology , Polydeoxyribonucleotides*/therapeutic use , Polydeoxyribonucleotides*/pharmacology , SARS-CoV-2*, Humans ; Immunotherapy/methods ; Cytokine Release Syndrome/etiology ; Cytokine Release Syndrome/therapy ; Cytokine Release Syndrome/prevention & control ; Endothelium, Vascular/drug effects ; Endothelium, Vascular/metabolism ; Endothelium, Vascular/immunology

المؤلفون: Richardson PG; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA. paul_richardson@dfci.harvard.edu., Perrot A; CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'Hématologie, Toulouse., Miguel JS; Clínica Universidad de Navarra, Navarra, CCUN, CIMA, IDISNA, CIBER-ONC, Pamplona., Beksac M; Department of Hematology, Ankara University, Ankara, Turkey., Spicka I; General Faculty Hospital, Prague, Czech Republic; First Faculty of Medicine, Charles University, Prague, Czech Republic., Leleu X; Service d'Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402, Poitiers Cedex., Schjesvold F; Oslo Myeloma Center, Department of Haematology, Oslo University Hospital, Oslo, Norway; KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway., Moreau P; Hematology Department, CHU Nantes, Nantes., Dimopoulos MA; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece., Huang SY; Department of Hematology, National Taiwan University Hospital, Taipei, Taiwan., Minarik J; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic., Cavo M; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Seràgnoli Institute of Hematology, and the Department of Medical and Surgical Sciences, Bologna University School of Medicine, Bologna, Italy., Prince HM; Immunology and Molecular Oncology, Epworth Healthcare, University of Melbourne, Melbourne, VIC, Australia., Macé S; Sanofi, Vitry-sur-Seine., Zhang R; Sanofi, Cambridge, MA., Dubin F; Sanofi, Vitry-sur-Seine., Morisse MC; Sanofi, Cambridge, MA., Anderson KC; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA.

المصدر: Haematologica [Haematologica] 2024 Jul 01; Vol. 109 (7), pp. 2239-2249. Date of Electronic Publication: 2024 Jul 01.

نوع المنشور: Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III

بيانات الدورية: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/drug therapy , Multiple Myeloma*/mortality , Multiple Myeloma*/pathology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Dexamethasone*/administration & dosage , Thalidomide*/analogs & derivatives , Thalidomide*/administration & dosage , Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/therapeutic use, Humans ; Male ; Aged ; Female ; Middle Aged ; Aged, 80 and over ; Adult ; Drug Resistance, Neoplasm ; Treatment Outcome ; Recurrence ; Survival Analysis

المؤلفون: Silbermann R; Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA., Laubach J; Department of Medical Oncology, Dana-Farber/Partners Cancer Care, Boston, Massachusetts, USA., Kaufman JL; Department of Mematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA., Sborov DW; Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah, USA., Reeves B; Division of Hematology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA., Rodriguez C; Department of Hematology and Medical Oncology, Mount Sinai School of Medicine, New York, New York, USA., Chari A; Department of Hematology and Medical Oncology, Mount Sinai School of Medicine, New York, New York, USA., Costa LJ; Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA., Anderson LD Jr; Division of Hematology/Oncology, Simmons Comprehensive Cancer Center, UT Texas Southwestern Medical Center, Dallas, Texas, USA., Nathwani N; Division of Myeloma, Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA., Shah N; Department of Medicine, University of California San Francisco, San Francisco, California, USA., Bumma N; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA., Holstein SA; Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, Nebraska, USA., Costello C; Division of Blood and Marrow Transplantation, Moores Cancer Center, University of California San Diego, La Jolla, California, USA., Jakubowiak A; Medicine- Hematology and Oncology, University of Chicago, Chicago, Illinois, USA., Orlowski RZ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Shain KH; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Cowan AJ; Department of Medicine, University of Washington, Seattle, Washington, USA., Gries KS; Janssen Research & Development, Raritan, New Jersey, USA., Pei H; Janssen Research & Development, LLC, Titusville, New Jersey, USA., Cortoos A; Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, USA., Patel S; Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, USA., Lin TS; Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, USA., Voorhees PM; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health/Wake Forest University School of Medicine, Charlotte, North Carolina, USA., Usmani SZ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Richardson PG; Department of Medical Oncology, Dana-Farber/Partners Cancer Care, Boston, Massachusetts, USA.

المصدر: American journal of hematology [Am J Hematol] 2024 Jul; Vol. 99 (7), pp. 1257-1268. Date of Electronic Publication: 2024 Apr 15.

نوع المنشور: Journal Article; Clinical Trial, Phase II; Multicenter Study; Randomized Controlled Trial

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/drug therapy , Quality of Life* , Bortezomib*/administration & dosage , Bortezomib*/therapeutic use , Dexamethasone*/administration & dosage , Dexamethasone*/therapeutic use , Lenalidomide*/administration & dosage , Lenalidomide*/therapeutic use , Patient Reported Outcome Measures* , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antibodies, Monoclonal*/therapeutic use , Antibodies, Monoclonal*/administration & dosage, Humans ; Male ; Female ; Middle Aged ; Aged ; Adult